ロード中...
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del‐CFTR
Rationale: In a prior study, lumacaftor/ivacaftor treatment (≤28 d) in patients with cystic fibrosis (CF) heterozygous for F508del-CFTR did not improve lung function. Objectives: To evaluate an optimized lumacaftor/ivacaftor dosing regimen with a longer duration in a cohort of patients heterozygous...
保存先:
| 出版年: | Ann Am Thorac Soc |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Thoracic Society
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5461999/ https://ncbi.nlm.nih.gov/pubmed/27898234 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1513/AnnalsATS.201609-689OC |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|